Publicaciones en colaboración con investigadores/as de Institute Catalá Oncología (19)

2024

  1. Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation

    Journal of Infectious Diseases, Vol. 229, Núm. 1, pp. 83-94

2023

  1. Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry

    Frontiers in Immunology, Vol. 14

  2. Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study

    BMJ open, Vol. 13, Núm. 7, pp. e071371

2022

  1. Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience

    Cancers, Vol. 14, Núm. 11

2021

  1. Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers

    Transplantation and Cellular Therapy, Vol. 27, Núm. 6, pp. 493.e1-493.e8

2020

  1. Predicting Mortality after Autologous Transplant: Development of a Novel Risk Score

    Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 10, pp. 1828-1832

2019

  1. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study

    The Lancet Haematology, Vol. 6, Núm. 2, pp. e89-e99

2018

  1. PD-1 genotype of the donor is associated with acute graft-versus-host disease after HLA-identical sibling donor stem cell transplantation

    Annals of Hematology, Vol. 97, Núm. 11, pp. 2217-2224

2015

  1. Outcome of graft failure after allogeneic stem cell transplant: Study of 89 patients

    Leukemia and Lymphoma, Vol. 56, Núm. 3, pp. 656-662

2014

  1. Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation

    Haematologica, Vol. 99, Núm. 10, pp. 1632-1637

2007

  1. Tho adjusted International Prognostic Index and β-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma

    Haematologica, Vol. 92, Núm. 8, pp. 1067-1074

2004

  1. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: The GEL/TAMO experience

    Annals of Oncology, Vol. 15, Núm. 10, pp. 1504-1509

  2. Elderly age and prior autologous transplantation have a deleterious effect on survival following allogenic peripheral blood stem cell transplantation with reduced-intensity conditioning: Results from the Spanish multicenter prospective trial

    Bone Marrow Transplantation, Vol. 33, Núm. 5, pp. 477-482

2002

  1. Dynamic filters for the spectral analysis of random signals

    Measurement Techniques, Vol. 45, Núm. 5, pp. 544-551

  2. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes

    Blood, Vol. 100, Núm. 6, pp. 2243-2245

  3. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period

    Bone Marrow Transplantation, Vol. 29, Núm. 9, pp. 737-743

2001

  1. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: Results of a prospective multicentre study

    British Journal of Haematology, Vol. 115, Núm. 3, pp. 653-659

  2. Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor transplantation

    British Journal of Haematology, Vol. 114, Núm. 4, pp. 931-936

  3. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation

    Bone Marrow Transplantation, Vol. 28, Núm. 4, pp. 341-347